Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q3 2025 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q3 2025 Earnings Call Transcript November 4, 2025Harmony Biosciences Holdings, Inc. misses on earnings expectations.
Harmony Biosciences Holdings Inc. (HRMY)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Polaris Capital Management Bernard Horn | 36,100 | $1,350,862 | 0.11% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.00 | 339,476 | $8,147,424.00 | 10,651,120 | 2020-08-21 | Filing | |
| $34.30 | 3,922 | $134,524.60 | 42,702 | 2020-08-26 | Filing | |
| $34.20 | 823 | $28,146.60 | 38,780 | 2020-08-25 | Filing | |
| $24.00 | 132,503 | $3,180,072.00 | 4,409,803 | 2020-08-21 | Filing | |
| $34.30 | 3,057 | $104,855.10 | 37,957 | 2020-08-24 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $37.15 | 3,746 | $139,171.39 | 24,521 | 2026-01-26 | Filing | |
| $35.92 | 20,961 | $752,833.18 | 0 | 2026-01-15 | Filing | |
| $40.11 | 5,933 | $237,956.61 | 0 | 2025-12-12 | Filing | |
| $40.11 | 20,000 | $802,146.00 | 0 | 2025-12-12 | Filing | |
| $39.54 | 20,000 | $790,896.00 | 0 | 2025-12-05 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,813,357 | $180,115,819 | 0% | |
| 2. | 541,281 | $20,254,735 | 0.01% | |
| 3. | 297,228 | $11,122,271 | 0% | |
| 4. | 281,721 | $10,542,000 | 1.73% | |
| 5. | 252,575 | $9,451,356 | 0% |
News See All
10 Best Beaten Down Growth Stocks to Buy According to Analysts
On October 27, Tejas Dessai, Director of Research at Global X ETFs, joined CNBC Television for an interview to discuss how the big tech earnings this week are expected to impact the broader stock market...
H.C. Wainwright Reaffirms Buy on Harmony Biosciences Holdings, Inc. (HRMY) Despite Phase 3 Setback
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is among the best low-priced growth stocks to buy now. Analysts at H.C.
10 Best Low Priced Growth Stocks to Buy Now
One thing we know for sure: growth is everyone’s priority, and if that growth doesn’t come with a heavy price tag, that’s when the real game begins.
UBS Maintains a Buy Rating on Harmony Biosciences Holdings (HRMY), Sets a $50 PT
Harmony Biosciences Holdings, Inc.
12 Affordable Biotech Stocks to Invest In Now
On September 4, Mizuho healthcare strategist Jared Holz appeared on CNBC's ‘Power Lunch’ to talk about the changing sentiment in the healthcare sector, the differences in the biotech ETFs, and more...
Harmony Biosciences Holdings, Inc. (HRMY) Expands WAKIX With FDA Nod for Prader-Willi
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is a commercial-stage biopharmaceutical company focused on therapies for rare neurological diseases.
11 Cheap Biotech Stocks to Buy According to Hedge Funds
Mizuho's Jared Holz appeared on CNBC's "Closing Bell Overtime" on July 8 to talk about whether the biotech industry is prepared for a breakthrough.
Mizuho Lifts Harmony Biosciences Target to $50, Citing Confidence in Fragile X Trial
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the best cheap growth stocks to buy according to analysts.
H.C. Wainwright Remains a Buy on Harmony Biosciences Holdings (HRMY)
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) is one of the top most undervalued biotech stocks to buy now. H.C.
Hedge Fund Resource Center Billionaire Hedge Funds
